LEADER 03128nam  2200601 a 450 
001 9910465297803321
005 20170919011101.0
010   $a1-4462-0896-6
035   $a(CKB)2560000000071722
035   $a(EBL)680649
035   $a(OCoLC)713010271
035   $a(SSID)ssj0001191008
035   $a(PQKBManifestationID)11663196
035   $a(PQKBTitleCode)TC0001191008
035   $a(PQKBWorkID)11203155
035   $a(PQKB)10286745
035   $a(MiAaPQ)EBC680649
035   $a(EXLCZ)992560000000071722
100   $a20130515d2011      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aBiosimilars handbook$b[electronic resource]
205   $a2nd ed.
210   $a[London] $cSAGE$d2011
215   $a1 online resource (56 p.)
300   $aDescription based upon print version of record.
311   $a1-4462-0775-7 
320   $aIncludes bibliographical references.
327   $a""Front Cover ""; ""Contents""; ""Introduction ""; ""What this handbook covers ""; ""Whom this handbook for ""; ""Executive Summary ""; ""The importance of biosimilar medicines""; ""The health economic benefits from biosimilar medicines""; ""Nomenclature of biopharmaceuticals, including biosimilar medicines""; ""List of European Commission-approved biosimilar medicines""; ""The science and technology of biosimilar medicines""; ""Regulation of biosimilar medicines""; ""Introduction of biosimilar medicines into clinical practice""; ""The future and evolving landscape of biosimilar medicines""
327   $a""Further information""""Contributors""; ""Glossary""; ""Acronyms and  Abbreviations""; ""Appendix""; ""Back Cover""
330   $aThis handbook aims to provide updated information on the current progress of biosimilar medicines in the European Union (EU). The first edition of this short guide to biosimilar medicines was published in 2007. At the time of first publication, only 5 biosimilar medicines had been approved in Europe, and both the legislation and concepts for these products were very new. Now the situation has developed and changed, as will be described herein, and the clinical and health economic benefits offered by biosimilar medicines to patients, clinicians and healthcare providers are considerably clearer.
606   $aPharmaceutical biotechnology$vHandbooks, manuals, etc
606   $aPharmaceutical biotechnology industry$vHandbooks, manuals, etc
606   $aDrugs$xGeneric substitution$vHandbooks, manuals, etc
606   $aPharmaceutical policy$vHandbooks, manuals, etc
606   $aBiological products$vHandbooks, manuals, etc
608   $aElectronic books.
615  0$aPharmaceutical biotechnology
615  0$aPharmaceutical biotechnology industry
615  0$aDrugs$xGeneric substitution
615  0$aPharmaceutical policy
615  0$aBiological products
676   $a615.19 22
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910465297803321
996   $aBiosimilars handbook$92108848
997   $aUNINA